We aim for sustainable performance over time to benefit patients, employees, shareholders and society. Solid financial results and maintaining the trust of society underpin our ability to create value.
Investor Update on Access & Sustainability
Investors Event Calendar
Third quarter & Nine months 2022 results
Environmental, Social and Governance (ESG)
ESG Updates: Oct 31, 2022 (PDF 0.5 MB) | July 20, 2022 (PDF 0.4 MB) | Apr 27, 2022 (PDF 0.7 MB) | Feb 03, 2022 (PDF 1.7 MB)
Latest updates: Novartis Enterprise Risk Management (PDF 0.2 MB) | Materiality Assessment
We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.
Stocks
Novartis Annual Reporting Suite
Read and download our integrated report, annual regulatory filings, and other disclosures.
Media Releases
Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH
New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four years
Sandoz announces further investment in key manufacturing facility in Austria, to support increased global demand for essential antibiotics
Pulse Updates
December 16, 2021
Novartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease
September 28, 2021
FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
Investor Relations Contacts
For questions about investor relations or the share registry, please contact our team.
Stay Up-to-Date
Stay connected to the latest news and information from Novartis
Novartis AG
Lichtstrasse 35
CH-4056 Basel, Switzerland